Central Retinal Vein Occlusion

Overview of diagnosis and treatment of central retinal vein occlusion.

What is a Central Retinal Vein Occlusion?

The inner layers of the retina receive their blood supply from the central retinal artery. The blood returns to the heart through the central retinal vein. Both vessels enter the eye through a small opening in the middle of the optic nerve. Either because this opening shrinks or because the artery hardens or because of circulations problems, the central retinal vein can become partially or completely occluded. When a patient develops a central retinal vein occlusion (CRVO), they lose some or most of their central vision. The photograph of the retina on the right is of an eye with 20/50 visual acuity with a central retinal vein occlusion for 6 weeks. The retinal veins dilate and there are retinal hemorrhages. Patients often develop swelling of the central retina-cystoid macular edema--causing some of the vision loss. Without treatments, 25% of eyes improve, 50% stabilize, and 25% worsen.

Lucentis for Central Retinal Vein Occlusion

Monthly Lucentis therapy is also helpful in improving vision in patients with central retinal vein occlusion and macular edema. Without treatment about 15 percent of have visual improvement. With treatment about 50 percent of patients have improved vision. Long term follow-up show that at 4 years, a little over half of the patients with central retinal vein occlusion require continued treatment to maintain the visual benefit.


Eylea for Central Retinal Vein Occlusion

Monthly Eylea therapy is also helpful in improving vision in patients with central retinal vein occlusion and macular edema. Without treatment about 15 percent of have visual improvement. With treatment about 60 percent of patients have improved vision.


Central Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Central Retinal Vein Occlusion

This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Retinal Vein Occlusion Market move up at a CAGR of 11.2% by Topmost Players | By Types Branch Retinal Artery ...
MENAFN.COM
The global retinal vein occlusion market is segmented on the basis of type, condition, diagnosis, treatment, and end user. On the basis of the type, it is segmented into branch retinal artery occlusion and central retinal vein occlusion. On the basis ...

and more »

Marea Informative

Federated Investors Inc. PA Has $868000 Position in Regeneron Pharmaceuticals Inc (REGN)
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
SEC FORM 4 - SEC.govSEC.gov
SEC FORM 4 - SEC.govSEC.gov

all 108 news articles »

Nasdaq

Regeneron Gains on Eylea, Dupixent and Pipeline Progress
Nasdaq
Eylea is approved in the United States, EU, Japan and other countries for the treatment of wet AMD, diabetic macular edema (DME), macular edema following retinal vein occlusion, which includes macular edema following central retinal vein occlusion and ...

and more »

Economic Times

High systolic BP affects your retina and may lead to complete vision loss
Economic Times
In fact, patients who suffer from continuous high systolic blood pressure are 280% more prone to developing severe eye conditions like Central Retinal Vein Occlusion, a condition wherein the central vision is affected leading to loss of sight, than ...


Retinal Vein Occlusion Market Share Analysis 2018 | Registering 11.2% of A CAGR with Renowned Players ...
MENAFN.COM
(MENAFN Editorial) This report provides in-depth qualitative and overall analysis of the' Retinal Vein Occlusion Market' on a regional level from 2018 to 2023. The study also provides a comprehensive review of restraints, Market Dynamics, drivers and ...

and more »

Morse Asset Management Inc Has $2.09 Million Stake in Regeneron Pharmaceuticals Inc (REGN)
Marea Informative (blog)
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Daily Industry Reports

Retinal Vein Occlusion Market Symptoms, Transmission, Diagnosis, Treatment and Prevention 2018
Daily Industry Reports
Global Retinal Vein Occlusion Market Research Report 2018- This report studies the global Retinal Vein Occlusion Market status and forecast, categorizes the global Retinal Vein Occlusion market size (value & volume) by manufacturers, type, application, ...

and more »

Bel Marra Health

If You Have High Blood Pressure, You're at Risk for This
Bel Marra Health
Studies have found that patients who experience continuously high systolic blood pressure are 280 percent more likely to develop Central Retinal Vein Occlusion (CRVO). CRVO causes central vision to become impaired, ultimately leading to vision loss.

and more »

Clearside Biomedical: Buy Or Sell Before 2018 Catalysts
Seeking Alpha
The 8-week data from the first phase 3 trial (SAPPHIRE) in treating macular edema due to retinal vein occlusion is expected in Q4 (a big binary event for the stock). Based on the borderline statistical significance in ... The secondary endpoints are ...

and more »

A potential new way to treat some of the most common blinding diseases
Science Daily
Many eye diseases, including diabetic retinopathy and macular degeneration, exhibit increased permeability of blood vessels in the macular (central) portion of the retina leading to abnormal fluid accumulation and vision loss. ... "Our research may ...


Fairfield Current

Sterling Capital Management LLC Has $566000 Stake in Regeneron Pharmaceuticals Inc (REGN)
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Fairfield Current

Gabelli Funds LLC Has $862000 Position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
SEC FORM 4 - SEC.govSEC.gov

all 68 news articles »

XNewsPress

Raymond James & Associates Grows Position in Regeneron Pharmaceuticals Inc (REGN)
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
SEC FORM 4 - SEC.govSEC.gov

all 56 news articles »

Flagship Harbor Advisors LLC Takes Position in Regeneron Pharmaceuticals Inc (REGN)
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.


XNewsPress

Regeneron Pharmaceuticals Inc (REGN) Given Average Rating of “Hold” by Analysts
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
SEC FORM 4 - SEC.govSEC.gov
SEC FORM 4 - SEC.govSEC.gov

all 102 news articles »

The Casual Smart

Regeneron Pharmaceuticals Inc (REGN) Shares Bought by Great West Life Assurance Co. Can
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Regeneron Pharmaceuticals, Inc. - REGN - Stock Price Today - ZacksZacks
Will Regeneron Close At $400?Seeking Alpha
Regeneron: A Buy On Dupixent And PipelineSeeking Alpha

all 89 news articles »

Spark Investment Management LLC Purchases Shares of 13500 Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

PressOracle

Schwab Charles Investment Management Inc. Trims Holdings in Regeneron Pharmaceuticals Inc (REGN)
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
SEC FORM 4 - SEC.govSEC.gov

all 31 news articles »

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in ...
Dove Medical Press
... months after the first injection included Snellen best-corrected visual acuity (BCVA), central retinal thickness (CRT) by time-domain optical coherence tomography (TD-OCT) or spectral-domain optical coherence tomography (SD-OCT), anti-VEGF ...

and more »

Fairfield Current

Swiss National Bank Raises Position in Regeneron Pharmaceuticals Inc (REGN)
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
SEC FORM 4 - SEC.govSEC.gov

all 107 news articles »

Fairfield Current

Cornerstone Wealth Management LLC Buys Shares of 103937 Regeneron Pharmaceuticals Inc (REGN)
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
SEC FORM 4 - SEC.govSEC.gov
SEC FORM 4 - SEC.govSEC.gov

all 51 news articles »

Thorold News

5680 Shares in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Purchased by Altman Advisors Inc.
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
SEC FORM 4 - SEC.govSEC.gov
SEC FORM 4 - SEC.govSEC.gov

all 108 news articles »

Medgadget (blog)

Retinal Vein Occlusion Market Rising Demand Seen in Healthcare at a CAGR of 11.2% by 2023 | By Types Branch ...
Medgadget (blog)
The global retinal vein occlusion market is segmented on the basis of type, condition, diagnosis, treatment, and end user. On the basis of the type, it is segmented into branch retinal artery occlusion and central retinal vein occlusion. On the basis ...


WPLG Local 10

Vasular condition leads to sudden sight loss
WPLG Local 10
Burgess was diagnosed with central retinal vein occlusion, or CRVO, a condition that causes a clot to form in the eye, leading to damaging pressure. "It was like someone threw a tomato at my eye," Burgess said. Cardiologist Dr. Adam Splaver said CRVO ...


IOP spikes more likely after treatment in certain patients
Healio
Patients with uveitis had the greatest mean IOP spike (24.3 mm Hg) compared with patients with central retinal vein occlusion (21.8 mm Hg), branch retinal vein occlusion (21.1 mm Hg) and (20.7 mm Hg) after a single injection. – by Robert Linnehan.


Six-month results of intravitreal ranibizumab for macular edema after branch retinal vein occlusion in a single ...
Dove Medical Press
Patients and methods: The inclusion criteria included a minimal patient age of 18 years, 20 letters or more best-corrected visual acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] score, 77 letters or less), and central retinal ...


Comparison between intravitreal bevacizumab and posterior sub-tenon injection of triamcinolone acetonide in macular ...
Dove Medical Press
Poorer final vision was associated with poorer baseline BCVA and diagnosis of central retinal vein occlusion after adjustment for age and sex (p<0.001 and 0.012, respectively). Significant elevation of IOP was noted at 3 months in the PSTA group, but ...


Ozurdex for retinal vein occlusion approved in China
Healio
The Chinese Food and Drug Administration has approved Ozurdex to treat adults with macular edema after branch retinal vein occlusion or central retinal vein occlusion, according to a press release from Allergan. Ozurdex (dexamethasone intravitreal ...


Medgadget (blog)

Retinal Vein Occlusion Market Size and Trend by Branch and Central Retinal Vein Occlusion Type, Etc. Types and ...
Medgadget (blog)
Glaucoma is a condition where the eye pressure causes damage to the optic nerve. The increasing number of patients with glaucoma is leading the retinal vein occlusion market offering a huge growth opportunity to the market players. Moreover, the ...

and more »

Ozurdex® (dexamethasone 0.7mg) now available for millions of patients in China with macular edema secondary to ...
Markets Insider
Ozurdex® is the first approved intravitreal injection for RVO in China and is licensed for the treatment of macular edema following BRVO and CRVO. Allergan has accelerated access to this treatment in 27 hospitals across China, making it available as a ...

» Load more